This retrospective study looked at 22 adult patients who had confirmed PSC and IBD and who had been on oral vancomycin for a period of time. 15 of the 22 patients (68.2%) had less therapy intensification on oral vancomycin therapy compared to off oral vancomycin therapy. There were also less steroid prescriptions for those taking […]
Oral Vancomycin Induced and Maintained Clinical and Endoscopic Remission in Ulcerative Colitis and Primary Sclerosing Cholangitis Post-liver Transplantation
This case study followed a 34-year-old man with PSC and ulcerative colitis who did not respond to multiple advanced therapies, and who had a liver transplant. Before his liver transplant, he tried mesalamine and Remicade without achieving remission. After his liver transplant, his UC flared and he tried Remicade, Entyvio, Humira, Xeljanz, and Stelara. However, […]
Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium
In this retrospective study, the Paediatric PSC Consortium compared the health of patients with PSC and IBD who had taken oral vancomycin (OV) to PSC-IBD patients who had not taken OV. Out of 113 patients with PSC-IBD, 70 were treated with OV, and they had a better chance of their IBD going into remission compared […]
Microbiome Responses to Vancomycin Treatment in a Child With Primary Sclerosing Cholangitis and Ulcerative Colitis
This case report shares the positive changes in the microbiome after a nine-year-old by took vancomycin for 90 days. Thanks to vancomycin, his ulcerative colitis symptoms resolved, his fecal calprotectin normalized, and his GGT (a liver function test that helps monitor PSC) declined and returned to normal levels!
Oral Vancomycin Induces Sustained Deep Remission in Adult Patients with Ulcerative Colitis and Primary Sclerosing Cholangitis
This paper is a collection of three brief case reports that describes the effect of oral vancomycin treatment in three patients with UC and PSC. All three patients achieved clinical remission and mucosal healing with vancomycin. The patients took 500 mg twice a day. Maintenance treatment with oral vancomycin led to sustained clinical and endoscopic […]
Effects of Antibiotic Therapy in Primary Sclerosing Cholangitis with and without Inflammatory Bowel Disease
This paper reviews the results of five studies that investigated the use of antibiotics (vancomycin, metronidazole, rifaximin, and minocycline) in 124 PSC patients. Specifically, this paper analyzes the impacts of the antibiotics on the following biomarkers: Mayo PSC Risk Score (MRS), ALP, total serum bilirubin, and adverse events.